MedTrace Logo

Determining the Safety of L-serine in ALS

NCT01835782 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2015-07-30

No results posted yet for this study

Summary

The purpose of this study is to determine the safety of L-Serine in subjects with Amyotrophic Lateral Sclerosis (ALS) at varied doses.

Conditions

  • Amyotrophic Lateral Sclerosis (ALS)

Interventions

DRUG

L-Serine

Sponsors & Collaborators

  • Institute for Ethnomedicine

    collaborator UNKNOWN

  • Phoenix Neurological Associates, LTD

    lead OTHER

Principal Investigators

  • Todd D Levine, MD · Phoenix Neurological Associates, LTD

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2016-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01835782 on ClinicalTrials.gov